Details for Patent: 9,072,697

Which drugs does patent 9,072,697 protect, and when does it expire?

Patent 9,072,697 protects OSMOLEX ER and is included in one NDA.

This patent has four patent family members in three countries.

Summary for Patent: 9,072,697

Title:	Composition and method for treating neurological disease
Abstract:	Disclosed are compositions comprising amantadine, or a pharmaceutically acceptable salt thereof, and one or more excipients, wherein at least one of the excipients modifies release of amantadine. Methods of administering the same are also provided.
Inventor(s):	Went; Gregory T. (Mill Valley, CA), Fultz; Timothy J. (Jasper, GA)
Assignee:	Adamas Pharmaceuticals, Inc. (Emeryville, CA)
Application Number:	14/591,641
Patent Claim Types: see list of patent claims	Use; Composition; Formulation; Device;

Drugs Protected by US Patent 9,072,697

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-001	Feb 16, 2018		DISCN	Yes	No						TREATMENT OF PARKINSON'S DISEASE
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-001	Feb 16, 2018		DISCN	Yes	No						TREATMENT OF DRUG-INDUCED EXTRAPYRAMIDAL REACTIONS IN ADULT PATIENTS WITH PARKINSON'S DISEASE
Supernus Pharms	OSMOLEX ER	amantadine hydrochloride	TABLET, EXTENDED RELEASE;ORAL	209410-004	Apr 22, 2020		DISCN	Yes	No						TREATMENT OF PARKINSON'S DISEASE

International Family Members for US Patent 9,072,697

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2588296
European Patent Office	1845968
European Patent Office	2623099